RxDoctor Payments Data

Iraklis Pipinos, MD

Vascular Surgery · Omaha, NENPI 1508816976

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (55.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Daiichi Sankyo Inc. accounts for 99.7% of it on its own, with 1 other manufacturer making up the rest.

$23,670in general payments, 2019–2025

Across 14 payments — averaging $1690.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$24K
  • Merck$71
$96,553in research payments, 2019–2025

Across 638 payments — averaging $151.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$97K

What the payments were for

  • Consulting fees$10,36044%
  • Travel & lodging$13,06955%
  • Food & beverage$2411%

General payments by program year

22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Daiichi Sankyo Inc.13$23,599
Merck1$71

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,670 in reported general payments places this provider in the 85th percentile of 35 vascular surgery providers in Nebraska.

See all vascular surgery providers in Nebraska

Medicare billing

Part B allowed, 2024
$12,151
Medicare patients
22
Services billed
48

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other vascular surgery in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →